EGFR and benign prostatic hyperplasia: We propose a core scientific hypothesis: CEP may block the process of prostate matrix hyperplasia by inhibiting the EGFR/PI3K/AKT signaling cascade and the expression of its downstream fibronectin FN1, providing a new strategy for the targeted treatment of BPH.